Global Disease Burden Estimates of Respiratory Syncytial Virus–Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis

Respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) constitutes a substantial disease burden in older adults aged ≥65 years. We aimed to identify all studies worldwide investigating the disease burden of RSV-ARI in this population. We estimated the community incidence, hospitalization rate, and in-hospital case-fatality ratio (hCFR) of RSV-ARI in older adults, stratified by industrialized and developing regions, using data from a systematic review of studies published between January 1996 and April 2018 and 8 unpublished population-based studies. We applied these rate estimates to population estimates for 2015 to calculate the global and regional burdens in older adults with RSV-ARI in…

• BA
  Bill and Melinda Gates Foundation
• P
  Pfizer
• A
  AstraZeneca
• G
  GlaxoSmithKline
• S
  Sanofi
• WH
  World Health Organization
• GS
  Gilead Sciences
• UO
  University of Rochester
• ER
  European Respiratory Society
• WT
  Wellcome Trust
• BS
  British Society for Immunology
• EF
  European Federation of Pharmaceutical Industries and Associations

  Award: 116019
• N
  Novavax
• NI
  National Institute for Health and Care Research
• IC
  Imperial College London
• UO
  University of Oxford
• EC
  European Commission

  Award: 116019
• UA
  Universiteit Antwerpen
• NI
  National Institutes of Health
• CF
  Centers for Disease Control and Prevention
• SP
  Sanofi Pasteur
• MR
  Medical Research Council

  Awards: MR/R502121/1, MC_PC_17220
• SS
  Statens Serum Institut
• FI
  Fogarty International Center